HF51116
MIF-IN-2
Daclizumab
CCR4 antagonist 2
(6E)-1,7-Bis(4-hydroxyphenyl)-6-hepten-3-one
MIF-IN-5
Cibisatamab
Glofitamab
Etokimab
NRP1 antagonist 1
Isoandrographolide
CXCR2 antagonist 4
Rafutrombopag (tautomerism)
Foralumab
Eldelumab
Cemiplimab
Emapalumab
Carlumab
Fezakinumab
Risankizumab